RAPT THERAPEUTICS, INC. (RAPT): Price and Financial Metrics


-0.61 (-2.18%)

POWR Rating

Component Grades













Add RAPT to Watchlist
Sign Up

Industry: Biotech



in industry


  • RAPT scores best on the Sentiment dimension, with a Sentiment rank ahead of 57.95% of US stocks.
  • The strongest trend for RAPT is in Growth, which has been heading down over the past 177 days.
  • RAPT ranks lowest in Momentum; there it ranks in the 5th percentile.

RAPT Stock Summary

  • With a price/sales ratio of 359.64, RAPT THERAPEUTICS INC has a higher such ratio than 98.92% of stocks in our set.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 1.1 for RAPT THERAPEUTICS INC; that's greater than it is for merely 8.71% of US stocks.
  • As for revenue growth, note that RAPT's revenue has grown -47.63% over the past 12 months; that beats the revenue growth of just 4.09% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to RAPT THERAPEUTICS INC are QURE, ENTA, TSVT, XENE, and MRUS.
  • RAPT's SEC filings can be seen here. And to visit RAPT THERAPEUTICS INC's official web site, go to www.rapt.com.

RAPT Valuation Summary

  • In comparison to the median Healthcare stock, RAPT's price/earnings ratio is 147.14% lower, now standing at -10.7.
  • Over the past 39 months, RAPT's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for RAPT.

Stock Date P/S P/B P/E EV/EBIT
RAPT 2023-01-20 369.2 4.5 -10.7 -10.4
RAPT 2023-01-19 353.2 4.3 -10.2 -10.0
RAPT 2023-01-18 340.4 4.1 -9.9 -9.6
RAPT 2023-01-17 350.3 4.2 -10.1 -9.9
RAPT 2023-01-13 344.6 4.2 -10.0 -9.7
RAPT 2023-01-12 348.4 4.2 -10.1 -9.8

RAPT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • RAPT has a Quality Grade of D, ranking ahead of 15.97% of graded US stocks.
  • RAPT's asset turnover comes in at 0.034 -- ranking 343rd of 682 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows RAPT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.034 1 -0.626
2021-03-31 0.043 1 -0.647
2020-12-31 0.037 1 -0.651
2020-09-30 0.030 1 -0.885
2020-06-30 0.020 1 -1.302
2019-12-31 0.000 NA 97.551

RAPT Price Target

For more insight on analysts targets of RAPT, see our RAPT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $62.14 Average Broker Recommendation 1.43 (Moderate Buy)

RAPT Stock Price Chart Interactive Chart >

Price chart for RAPT

RAPT Price/Volume Stats

Current price $27.35 52-week high $32.45
Prev. close $27.96 52-week low $9.85
Day low $27.04 Volume 97,353
Day high $28.11 Avg. volume 438,486
50-day MA $20.81 Dividend yield N/A
200-day MA $20.53 Market Cap 818.07M


Rapt Therapeutics, Inc. operates as a clinical stage immunology-based biopharmaceutical company. It focuses on discovering, developing and commercializing oral small molecule therapies for patients in oncology and inflammatory diseases.. The company was founded in 2015 and is headquartered in South San Francisco, CA.

RAPT Latest News Stream

Event/Time News Detail
Loading, please wait...

RAPT Latest Social Stream

Loading social stream, please wait...

View Full RAPT Social Stream

Latest RAPT News From Around the Web

Below are the latest news stories about RAPT THERAPEUTICS INC that investors may wish to consider to help them evaluate RAPT as an investment opportunity.

Here's Why 'Trend' Investors Would Love Betting on Rapt Therapeutics (RAPT)

Rapt Therapeutics (RAPT) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Yahoo | January 25, 2023

RAPT Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced that Brian Wong, M.D., Ph.D., President and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January

Yahoo | January 3, 2023

Does Rapt Therapeutics (RAPT) Have the Potential to Rally 122% as Wall Street Analysts Expect?

The mean of analysts' price targets for Rapt Therapeutics (RAPT) points to a 122.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Yahoo | December 30, 2022

Investors in RAPT Therapeutics (NASDAQ:RAPT) have unfortunately lost 44% over the last year

The simplest way to benefit from a rising market is to buy an index fund. But if you buy individual stocks, you can do...

Yahoo | December 17, 2022

Was anything positive for RAPT Therapeutics Inc. (RAPT) stock last session?

As of Tuesday, RAPT Therapeutics Inc.’s (NASDAQ:RAPT) stock closed at $18.57, up from $17.48 the previous day. While RAPT Therapeutics Inc. has overperformed by 6.24%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, RAPT fell by -41.20%, with highs and lows ranging from $40.74 to $9.85, […]

US Post News | December 14, 2022

Read More 'RAPT' Stories Here

RAPT Price Returns

1-mo 38.13%
3-mo 21.83%
6-mo 46.89%
1-year 37.71%
3-year -38.25%
5-year N/A
YTD 38.13%
2022 -46.09%
2021 85.97%
2020 -28.47%
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.9265 seconds.